Trials / Completed
CompletedNCT00359658
Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation
Conversion Study to Optimize Immunosuppressive Regimen by Withdrawal of Steroids, Cyclosporine A Dose Reduction and a Switch to Mycophenolatmofetile for Patients After Heart Transplantation in the Long-Term.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Hannover Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is first to improve or save renal function and second to decrease cardiac risk factors by optimising the immunosuppressive regimen by withdrawing steroids and reducing the Cyclosporine A dose. The concomitant administration of Mycophenolatmofetile, an effective immunosuppressive agent, will minimize the risk of acute rejection episodes.
Detailed description
The decrease of quality of life in patients after heart transplantation in the long-term is determined by an increasing incidence of transplant vasculopathy and by immunosuppression-related side effects. Calcineurin inhibitors are associated with chronic nephrotoxicity, while long-term administration of steroids results in an increased incidence of cardiovascular risk factors (e.g. hypertension, lipometabolic disorders, steroid induced diabetes, adipositas)and therefore, carries the potential of graft disfunction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | prednisolon | prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal |
| DRUG | Mycophenolatmofetile | Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily |
| DRUG | Cyclosporin A | Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-08-02
- Last updated
- 2009-02-13
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00359658. Inclusion in this directory is not an endorsement.